476 filings
Page 6 of 24
424B5
jvvkmaeptgavh0dd74
23 Apr 21
Prospectus supplement for primary offering
4:05pm
8-K
njug9 fit1tmeqbz
22 Apr 21
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
9:33am
424B5
xjnlb
21 Apr 21
Prospectus supplement for primary offering
4:03pm
EFFECT
1avbcde6ibzbz
15 Apr 21
Notice of effectiveness
12:15am
CORRESP
bvl3o3mgxug86jmjxk0u
12 Apr 21
Correspondence with SEC
12:00am
UPLOAD
zz13v
8 Apr 21
Letter from SEC
12:00am
8-K
gu3r9ia
26 Mar 21
Departure of Directors or Certain Officers
5:02pm
8-K
otdkufmuw1p
11 Feb 21
NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021
4:15pm
S-8
hq39lmcj jvnlzltpm5
11 Jan 21
Registration of securities for employees
5:16pm
8-K
1hxshekkk2 paak7
23 Dec 20
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020
4:10pm
8-K
6qtw vfrmueps9xk
16 Dec 20
Regulation FD Disclosure
9:00am
8-K
cyccm8o3l xpdqfq4
2 Dec 20
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
9:57am
8-K
nbtykd8u gtuxm044c
6 Oct 20
Entry into a Material Definitive Agreement
8:32am
8-K
v02dvy 392l
11 Sep 20
Other Events
5:06pm
8-K
0krpcvmzqpatj3
13 Aug 20
NeuBase Therapeutics Reports Financial Results for the Third Fiscal Quarter of 2020
4:11pm
8-K
qpjv27d
13 Aug 20
Submission of Matters to a Vote of Security Holders
8:00am